Haemonetics Co. to Post FY2027 Earnings of $5.92 Per Share, Zacks Research Forecasts (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Research analysts at Zacks Research boosted their FY2027 earnings estimates for Haemonetics in a research note issued to investors on Thursday, September 12th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $5.92 per share for the year, up from their previous forecast of $5.91. The consensus estimate for Haemonetics’ current full-year earnings is $4.58 per share.

Several other research firms have also issued reports on HAE. JMP Securities reiterated a “market outperform” rating and issued a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 13th. Citigroup decreased their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. Needham & Company LLC raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective on the stock in a report on Wednesday, June 12th. CL King started coverage on shares of Haemonetics in a report on Friday. They issued a “buy” rating and a $116.00 price target on the stock. Finally, BTIG Research began coverage on shares of Haemonetics in a report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $106.14.

Haemonetics Trading Up 0.8 %

HAE opened at $76.70 on Monday. The company’s 50 day moving average is $81.20 and its 200-day moving average is $84.05. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35. Haemonetics has a 1-year low of $70.74 and a 1-year high of $97.97. The company has a market cap of $3.91 billion, a P/E ratio of 33.49, a PEG ratio of 1.32 and a beta of 0.30.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). The firm had revenue of $336.17 million during the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The business’s revenue was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.05 EPS.

Insider Activity at Haemonetics

In other Haemonetics news, insider Stewart W. Strong sold 4,312 shares of the firm’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the transaction, the insider now directly owns 18,196 shares of the company’s stock, valued at $1,658,565.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Stewart W. Strong sold 4,312 shares of Haemonetics stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $91.15, for a total transaction of $393,038.80. Following the transaction, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Anila Lingamneni sold 2,136 shares of Haemonetics stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $90.00, for a total value of $192,240.00. Following the transaction, the executive vice president now directly owns 21,410 shares in the company, valued at $1,926,900. The disclosure for this sale can be found here. 1.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HAE. Charles Schwab Investment Management Inc. raised its holdings in Haemonetics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 534,694 shares of the medical instruments supplier’s stock valued at $45,722,000 after buying an additional 8,901 shares during the period. Dimensional Fund Advisors LP raised its holdings in Haemonetics by 7.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 826,731 shares of the medical instruments supplier’s stock valued at $70,697,000 after buying an additional 59,670 shares during the period. Principal Financial Group Inc. raised its holdings in Haemonetics by 2.3% during the 4th quarter. Principal Financial Group Inc. now owns 203,964 shares of the medical instruments supplier’s stock valued at $17,441,000 after buying an additional 4,604 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in Haemonetics during the 4th quarter valued at $390,000. Finally, Norges Bank purchased a new stake in Haemonetics during the 4th quarter valued at $28,591,000. 99.67% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.